Comparing my proprietary universe of cannabis stocks to the leading exchange-traded funds is a gratifying experience.
Sure, the funds like ETFMG Alternative Harvest ETF (ARCA:MJ) are up 40-43% year to date (YTD). My stocks have done a little better than that and, unlike most of the funds, our future looks even brighter.
Start with GW Pharmaceuticals PLC (NASDAQ:GWPH), which was the biggest component in funds like MJ. GWPH is a great drug developer. I’ve been recommending it since 2018 and was thrilled to see it surge 90% so far this year.
But it isn’t going to be around much longer once its $7 billion merger with Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is final. And that’s a problem for the funds that now need to scramble to fill the hole GWPH leaves behind.
Beyond that, their portfolios are packed with the big cultivators that never really worked for me as long-term investments: Aphria Corp. (NASDAQ:APHA), Canopy Growth Corp. (NYSE:CGC) and the rest.
My list, on the other hand, makes space for smaller and more interesting “Cannabis 2.0” stocks like OrganiGram Holdings Inc. (NASDAQ:OGI) and CannTrust Holdings (OTC:CNTTQ). That’s where the innovation and growth are.
And that’s where I’m focused. IPO Edge has a few fresh entry points. I’d be happy to share them with you.
P.S. Orlando MoneyShow, Championsgate Resort, June 10-12: The MoneyShow is back in person! Speakers not only include me but Larry Kudlow, Mark Skousen, Bob Carlson, Jon Najarian, Jeffrey Saut, Jeff Hirsch and Louis Navallier. Click here to register or call 1-800-970-4355 and mention priority code 052705 to attend fr